Charles River Laboratories vs Illumina
Illumina reported revenue of $4.3 billion in fiscal 2025, about the same as Charles River Laboratories' $4.0 billion in fiscal 2025. Charles River Laboratories' revenue fell 0.8% in its latest year, and Illumina's fell 0.7%. Charles River Laboratories had an operating margin of 0.6%, against 18.6% at Illumina. Free cash flow was $518 million at Charles River Laboratories and $931 million at Illumina. Their fiscal years end in different months (December 27 and December 28), so the periods don't line up exactly.
Side by side
| Charles River Laboratories | Illumina | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 27, 2025 | FY2025, Dec 28, 2025 |
| Revenue | $4.0B | $4.3B |
| Revenue growth | −0.8% | −0.7% |
| Revenue growth a year, last 5 years | 6.5% | 6.0% |
| Gross margin | — | 66.1% |
| Operating margin | 0.6% | 18.6% |
| Net margin | −3.6% | 19.6% |
| Free cash flow | $518M | $931M |
| Free cash flow margin | 12.9% | 21.4% |
| Return on capital | 0.4% | 20.3% |
| Net debt to EBITDA | 4.5x | 0.3x |
| Dividends and buybacks | $361M | $742M |
| Change in diluted share count | −4.0% | −1.9% |
| Last close | $357.27 | $271.04 |
| P/E at the last close | — | 50.6× |
| Insider trades, last 12 months | bought $7,338, sold $52.1 million | bought $84,627, sold $592.9 million |
| Piotroski F-score | 4 of 8 | 8 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Charles River LaboratoriesIllumina
Operating margin
Percent of revenue
Charles River LaboratoriesIllumina
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Charles River LaboratoriesIllumina
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Charles River Laboratories and Illumina pages.